07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Sep 5, 2016 |  BioCentury  |  Finance

Medivation elation

Deep analysis and market timing converged to make Medivation Inc. (NASDAQ:MDVN) one of the biggest-ever biotech wins for Bain Capital Public Equity. The firm, which has been enjoying trading gains on the stock for the...